by The RxPx Team | Sep 16, 2026 | Articles
Patients are not waiting for healthcare organizations to decide how AI should fit into their care. They are already using it. That was one of the clearest messages from “AI Meets Empathy,” a session at the 2026 MAPA Medical Affairs Summit featuring Monisha Nair, Chief... by The RxPx Team | Sep 8, 2026 | Articles
For specialty therapies, adherence is rarely determined by a medication reminder alone. It is shaped by everything that happens around treatment: how quickly patients get started, whether they understand what to expect, how emerging barriers are identified, and... by The RxPx Team | Sep 1, 2026 | Articles
The most successful pharmaceutical launches don’t begin at approval. They begin when there’s still time to identify, and engineer out, preventable risk. By the time a therapy reaches Phase III clinical trials, it has progressed through years of clinical... by The RxPx Team | Aug 19, 2026 | Articles
FOR IMMEDIATE RELEASE RxPx Accelerates Growth with Leadership Expansion as AI-Powered Patient Safety and Support Platform Demonstrates Significant Gains in Adherence and Speed to Therapy Leadership expansion, strategic pharmaceutical partnerships and platform... by The RxPx Team | Jul 17, 2026 | Articles
Every pharmaceutical launch is measured against ambitious commercial forecasts. Brand teams spend years preparing for approval, market access, and physician uptake. Pharma invests upwards of $1-2 billion and 10+ years to bring a therapy to market. Yet once approved,... by The RxPx Team | Jul 7, 2026 | Articles
How Do We Embrace AI Without Compromising Ethics, Governance, and Trust? That was the central question explored during Medicines Australia’s recent webinar, Conversations & The Code: Compliance and Decision Making – Navigating AI and Emerging... 